(Total Views: 366)
Posted On: 02/09/2021 9:11:41 AM
Post# of 72446
Exactly my point, Kelt, it is a new game in the BP/bio startup relationship because of the change in dynamic of who did the work, accepted the risk, etc., etc.
Mainly wanted all investors to realize Brilacidin should be viewed differently from drugs in the past. One major reason besides us taking all the risks to get it to this point in time, but because of it's wide spectrum of uses throughout the entire body that it most likely IMO would be absolutely necessary for one BP to get the entire Brilacidin platform or else there is going to be a giant mess in crossover between BPs having separate licenses.
One additional point - Not 1 BP has helped us at any time in the last 8 years and IMO they have been the main factors trying to BK us. As such, I would be less inclined to give them any leeway or mercy than I would the IRS.
Mainly wanted all investors to realize Brilacidin should be viewed differently from drugs in the past. One major reason besides us taking all the risks to get it to this point in time, but because of it's wide spectrum of uses throughout the entire body that it most likely IMO would be absolutely necessary for one BP to get the entire Brilacidin platform or else there is going to be a giant mess in crossover between BPs having separate licenses.
One additional point - Not 1 BP has helped us at any time in the last 8 years and IMO they have been the main factors trying to BK us. As such, I would be less inclined to give them any leeway or mercy than I would the IRS.
(7)
(0)
